Reply to: Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy

Joanna A Krupka1, Alimu Dayimu1, Daniel J Hodson1

  • 1Joanna A. Krupka, MB PhD, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom, Department of Haematology, University of Cambridge, Cambridge, United Kingdom; Alimu Dayimu, PhD, Cambridge Clinical Trials Unit-Cancer Theme, University of Cambridge, Cambridge, United Kingdom; and Daniel J. Hodson, MB PhD, Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom, Department of Haematology, University of Cambridge, Cambridge, United Kingdom.

Summary

No abstract available in PubMed .